I-Mab (IMAB)
Stock Price:
$29.32 USD
-0.13 (-0.44%)
Updated Jul 8, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.67B |
| Revenue (ttm) |
4.29M |
| Net Income (ttm) |
-207.42M |
| Shares Out |
57.83M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 8, 2020 |
| Last Price |
$29.32 |
| Previous Close |
$29.45 |
| Change ($) |
-0.13 |
| Change (%) |
-0.44% |
| Day's Open |
29.65 |
| Day's Range |
28.63 - 29.75 |
| Day's Volume |
35,592 |
| 52-Week Range |
9.30 - 32.89 |
More Stats
| Market Cap |
1.67B |
| Enterprise Value |
1.52B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
57.83M |
| Float |
23.10M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-170.36 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
18,672 |
| Short Ratio |
0.24 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
390.37 |
| PB Ratio |
4.34 |
| Revenue |
4.29M |
| Operating Income |
-212.17M |
| Net Income |
-207.42M |
| Free Cash Flow |
-125.75M |
| Net Cash |
156.11M |
| Net Cash / Share |
2.74 |
| Gross Margin |
100.00% |
| Operating Margin |
-4,950.58% |
| Profit Margin |
-4,950.00% |
| FCF Margin |
-2,934.08% |
| ROA |
-44.52% |
| ROE |
-95.85% |
| ROIC |
7,497.30% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$31.70*
(8.12% upside)
Low
29.4
Current: 29.32
High
33.0
Target: 31.70
*Average 12-month USD price target from 3 stock analysts.
Financial Performance
Financial numbers in millions CNY.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 30.00 | 53.78 | 11.56 |
| Revenue Growth | -44.22% | 365.39% | - |
| Gross Profit | 30.00 | 53.78 | 11.56 |
| Operating Income | -1,485 | -455 | -279 |
| Net Income | -1,452 | -403 | -298 |
| Shares Outstanding | 7.38 | 6.53 | 5.74 |
| Earnings Per Share | -2,011.90 | -617.00 | -519.30 |
| Operating Cash Flow | -868 | -281 | -252 |
| Capital Expenditures | -12.24 | -14.41 | -20.33 |
| Free Cash Flow | -880 | -295 | -272 |
| Cash & Equivalents | 1,225 | 1,937 | 679 |
| Total Debt | 132 | 147 | 213 |
| Net Cash / Debt | 1,093 | 1,790 | 466 |
| Assets | 1,738 | 2,376 | 1,025 |
| Liabilities | 668 | 416 | 309 |
| Book Value | -2,035 | -955 | -300 |
Numbers in millions CNY, except per-share numbers.
Company Details
| Full Name |
I-Mab |
| Country |
China |
| Employees |
185 |
| CEO |
Huaqiong Shen |
Stock Information
| Ticker Symbol |
IMAB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMAB |
Description
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.